Mineralys Therapeutics, Inc.
NASDAQ:MLYSBiotechnology
+$0.37 today
- Market cap
- $1.22B
- Beta
- 0.56
- P/E (TTM)
- -13.9
- EPS (TTM)
- -$1.83
Volume 1.39M
Average 1.48M
MLYS Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Mineralys Therapeutics, Inc.NASDAQ: MLYS
Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Financing cash flow growth accelerates
Q2 FY2026 financing cash flow of $243.26M rose 2374.5% year over year, ahead of the +231.0% change in trailing-twelve-month financing cash flow. Sequentially, it rose 902.2% from the prior quarter. Over 3 fiscal years it compounded at +66.5% a year.
Context
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +2374.5% holds above the trailing-twelve-month pace of +231.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 591M USD
- Year-over-year change
- +408.9%
- 4-year CAGR
- +123.2%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 591M | +408.9% |
| FY2024 | 2024-12-31 | 116.14M | -42.9% |
| FY2023 | 2023-12-31 | 203.25M | +58.8% |
| FY2022 | 2022-12-31 | 128.02M | +437.6% |
| FY2021 | 2021-12-31 | 23.81M | — |
Financing Cash Flow vs competitors
How MLYS compares with its peers on the latest reported figures
- MLYS's LTM Jun 2026 financing cash flow of $659.43M is the largest of the 7 companies compared; the peer median is $142.24M.
- Its year-over-year change of +231.0% is the 3rd highest of 7, against a peer median of +218.7%.
- Over three fiscal years its annual growth of +66.5% compares with a peer median of +44.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $659.43M | +231.0% | +66.5% | — | |
| LTM Jun 2026 | $292.94M | -15.9% | +44.7% | — | |
| LTM Sep 2026 | $245.69M | +211.1% | — | 37.7% | |
| LTM Mar 2026 | $190.32M | -2.7% | +442.1% | 951.6% | |
| LTM Mar 2026 | $94.16M | +226.3% | -5.1% | 287.7% | |
| LTM Mar 2026 | $63.49M | +3167.7% | — | — | |
| LTM Mar 2026 | $44.68M | +269.7% | — | — | |
| Peer median (excluding MLYS) | $142.24M | +218.7% | +44.7% | 287.7% | |
Competitors are the stored peer set for MLYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (19.41M) | (29.8M) | (71.9M) | (177.81M) | (154.65M) |
| Depreciation & Amortization | 0 | 0 | 0 | 43K | 59K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 80K | 455K | 5.06M | 11.34M | 19.32M |
| Change in Working Capital | 4.09M | 772K | (7.47M) | 9.52M | 2.73M |
| Accounts Receivables | 0 | 0 | (355K) | 424K | (166K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 4.09M | 772K | (7.12M) | 9.1M | 2.9M |
| Other Non-Cash Items | 684K | (649K) | (6.87M) | (9.41M) | (9.88M) |
| Operating Cash Flow | (14.56M) | (29.22M) | (81.17M) | (166.31M) | (142.42M) |
| Capital Expenditures | 0 | 0 | 0 | (96K) | (15K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (71.76M) | (347.97M) | (373.45M) | (814.74M) |
| Sales of Investments | 0 | 50M | 187.5M | 488.5M | 425M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (21.76M) | (160.47M) | 114.96M | (389.75M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 23.81M | 0 | 202.99M | 116.06M | 591M |
| Common Stock Repurchased | 0 | (1.63M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 258K | 83K | 0 |
| Financing Cash Flow | 23.81M | 128.02M | 203.25M | 116.14M | 591M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 9.25M | 77.04M | (38.4M) | 64.79M | 58.83M |
| Free Cash Flow | (14.56M) | (29.22M) | (81.17M) | (166.41M) | (142.43M) |
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
Intrinsic Alpha fair value
Locked
Current Price
$13.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.